David M. Loeb, MD, PhD

David M. Loeb, MD, PhD, is chief of the Division of Pediatric Hematology, Oncology, and Cellular Therapy Children’s Hospital at Montefiore. He is also a professor in the Department of Pediatrics (Pediatric Hematology-Oncology) and Department of Development & Molecular Biology at Albert Einstein College of Medicine, and a member of Montefiore Einstein Comprehensive Cancer Center in Bronx, NY.

Articles by David M. Loeb, MD, PhD

DFMO shows promise in reducing metastasis in osteosarcoma and Ewing sarcoma, with phase 2 trials underway to test its role as maintenance therapy.

From the Lab to the Clinic: Exploring DFMO’s Potential to Prevent Metastatic Disease in Children With Osteosarcoma and Ewing Sarcoma

ByDavid M. Loeb, MD, PhD,Rachel Offenbacher, MD

October 1st 2025

DFMO shows promise in reducing metastasis in osteosarcoma and Ewing sarcoma, with phase 2 trials underway to test its role as maintenance therapy.

David M. Loeb, MD, PhD

Articles by David M. Loeb, MD, PhD

From the Lab to the Clinic: Exploring DFMO’s Potential to Prevent Metastatic Disease in Children With Osteosarcoma and Ewing Sarcoma

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma